AbCellera Biologics Inc Stock News
$3.69
1.93%
Nasdaq,
Nov 14, 10:18 pm CET
Index
Industry
AbCellera Biologics Inc Stock News
Neutral
Business Wire
●
7 days ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Stephen Quake to its Board of Directors.
Neutral
Seeking Alpha
●
10 days ago
AbCellera Biologics Inc. ( ABCL ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Tryn Stimart - Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer Carl L. Hansen - CEO, President & Chairperson Andrew Booth - Chief Financial Officer Conference Call Participants Malcolm Hoffman - BMO Capital Markets Equity Research Andrea Tan - Goldman Sac...
Neutral
Business Wire
●
11 days ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2025 Business Results.
Neutral
Business Wire
●
about one month ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in November and December 2025.
Positive
Seeking Alpha
●
about one month ago
AbCellera Biologics is poised for long-term growth as its clinical manufacturing facility nears completion, enabling in-house drug development and contract manufacturing revenue. ABCL's strategic pivot from a service provider to a proprietary drug developer targets high-growth monoclonal antibody markets, with promising candidates ABCL635 and ABCL575 entering clinical trials. Despite recent rev...
Neutral
Business Wire
●
about 2 months ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025.
Neutral
Business Wire
●
2 months ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer.
Neutral
Business Wire
●
3 months ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
